1994 Fiscal Year Final Research Report Summary
Immunopotentiation by immunoadjuvants of human viral vaccines
| Project/Area Number |
04304033
|
|---|
| Research Category |
Grant-in-Aid for Co-operative Research (A)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Immunology
|
|---|
| Research Institution | (Institute of Immunological Science) Hokkaido University |
|---|
Principal Investigator |
AZUMA Ichiro Hokkaido University, Institute of Immunological Science, Professor, 免疫科学研究所, 教授 (50028411)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
YAMANISHI Koichi Osaka University, Research Institute of Microbial Diseases, Professer, 微生物病研究所, 教授 (10029811)
MATSUURA Motohiro Jichi Medical School.Department of Microbiology, Associate Professor, 医学部, 助教授 (20150089)
TOKURA Seiichi Hokkaido University, Graduate School of Environmental Earth Science, Professor, 大学院・地球環境科学研究科, 教授 (40000806)
ISHIZUKA Masaaki Microbial Chemistry Research Foundation, Institute for Chemotherapy, Vice-direct, 付属化学療法研究所, 副所長 (80159722)
IKUTA Kazuyoshi Hokkaido University, Institute of Immunological Science, Professor, 免疫科学研究所, 教授 (60127181)
|
|---|
| Project Period (FY) |
1992 – 1994
|
| Keywords | Muramyldipeptide derivatives / Microbial-derived immunomodulators / Artificial polysaccharide immunoadjuvants / Lipid A derivatives / Synthetic DNA / Hanta virus / Component vaccine of influenza virus / HIV-6 |
|---|
| Research Abstract |
Recently, great advances have been made in the field of the developments of viral vaccines, especially recombinant proteins, synthetic peptides and purified components of viruses were developed as vaccines. These recombinant protein and synthetic peptide vaccines were shown to have weak antigenicity as vaccines and the application of effective immunoadjuvants is essentially required. In this research projects, both MDP derivatives, MDP-Lys(L18)and B30-MDP were reported to be effective adjuvants for vaccines. B30-MDP was shown to be effective for the potentiation of antigenicity of component vaccine of influenza virus and type B hepatitis recombinant vaccine. It was also found that MDP-Lys(L18)is effective as adjuvant in recombinant vaccine of type B hepatitis virus when both adjuvant and antigen were mixed as water solution and immunized in mice. B30-MDP was also shown to have adjuvant actibity for the production of circulating antibody and cell-mediated immunity to in activated vaccine and recombinant nuclear protein of Hanta virus. GLA-60, lipid A-related compound, was shown to have also potent adjuvant activity in recombinant type B hepatitis vaccine.
In this research project we have continued the study on the development of new immunoadjuvants for the vaccine, and several adjuvant-active substances such as chitosan oligomer, conagenin, synthetic DNA,teichoic acid, have been developed. As the antigens of virus vaccine development, the recombinant surface protein and nuclear protein of Hanta virus were prepared by recombinant gene technology. The infection models and antigenic analysis of HIV-1, HIV-6 and Hanta viruses were examined and the efficacy of immunoadjuvant to theses infection models is also discussed.
|
